Study shows Repatha can reduce chances of heart attacks and strokes

Based on 27,564 patient cardiovascular outcomes study, Amgen has established that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularizations.  
"We now show for the first time in a dedicated outcomes study that decreasing LDL cholesterol with PCSK9 inhibition results in clinically meaningful cardiovascular benefit," said Dr. Marc Sabatine, chairman of the TIMI Study Group and professor of medicine at Harvard Medical School.
The study showed that the use of Repatha could decrease a patient’s chance of a major adverse cardiovascular event by 20 percent. This benefit of Repatha starts in patients who take the drug for at least six months. The reduction in risk grows over time, going from 16 percent in the first year to 25 percent beyond that.
"This is a game changer for high-risk patients. Even though these patients were optimally treated with the latest therapies, they were still at high risk for an additional cardiac event. It's remarkable to see such a large impact in reducing cardiac events given that this patient population was only on Repatha for about two years," Dr. Sean Harper, executive vice president of Research and Development at Amgen, said.